We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART) (QD vs BID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00740025
Recruitment Status : Completed
First Posted : August 22, 2008
Last Update Posted : October 14, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:
This is a prospective randomized study evaluating dosing frequency of gonadotropin administration in ART cycles.

Condition or disease
Pregnancy

Detailed Description:
Using once daily or bid dosing of gonadotropins in ART has been arbitrary with no studies showing whether splitting the medication dose improves ART parameters. This study was undertaken to provide an answer to this important question.

Study Design

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Prospective Randomized Study of QD vs BID Dosing in ART
Study Start Date : January 2006
Primary Completion Date : January 2010
Study Completion Date : January 2010
Groups and Cohorts

Group/Cohort
QD
Women who received their meds as QD administration
BID
Women who received their gonadotropins as a BID dose


Outcome Measures

Primary Outcome Measures :
  1. Ongoing pregnancy [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. peak estradiol, number of follicles, number of oocytes, implantation rate, multiple pregnancy rate [ Time Frame: 1 year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women between 21-40 yo
Criteria

Inclusion Criteria:

  • women < 40 undergoing ART

Exclusion Criteria:

  • women > 40
  • endometriomas
  • severe cervical stenosis
  • testicular sperm
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00740025


Locations
United States, Virginia
Virginia Center for Reproductive Medicine
Reston, Virginia, United States, 20190
Sponsors and Collaborators
Virginia Center for Reproductive Medicine
Investigators
Principal Investigator: Fady I Sharara, M.D Virginia Center for Reproductive Medicine
More Information

Responsible Party: Fady I. Sharara, Virginia Center for Reproductive Medicine
ClinicalTrials.gov Identifier: NCT00740025     History of Changes
Other Study ID Numbers: 1-Sharara
First Posted: August 22, 2008    Key Record Dates
Last Update Posted: October 14, 2010
Last Verified: October 2010

Keywords provided by Virginia Center for Reproductive Medicine:
QD dose
BID dosing
peak estradiol
oocytes
implantation rate
pregnancy rate